NCT01584206|CompletedDMC
Sitosterolemia Metabolism
STAIR7002
Assessment of Sterol Metabolism in Sitosterolemia: A Pilot Study of Patients Treated With Ezetimibe
Loading search results
STAIR7002
Assessment of Sterol Metabolism in Sitosterolemia: A Pilot Study of Patients Treated With Ezetimibe
Sponsor study identifier
interventional
8
1 country
1
Study Start
April 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2013
Actual (reported)Study Completion
December 2016
Actual (reported)Ezetimibe has become the treatment choice for patients with sitosterolemia. Ezetimibe is an inhibitor of cholesterol absorption from the gastrointestinal tract. The purpose of this study is to determine if ezetimibe improves whole body plant sterol and cholesterol homeostasis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2016
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 2012
Date type not reportedThis date has not been verified as actual or estimated.
April 16, 2012
Actual (reported)April 24, 2012
Actual (reported)August 2013
Actual (reported)December 2016
Actual (reported)Plasma cholesterol level
Plasma cholesterol level will be assessed by GC
8 months
Plasma sitosterol level
Plasma plant sterol assessment using GC
8 months
Cholesterol absorption
4 month
Cholesterol synthesis
4 months
Compare on and off ezetimibe
10mg ezetimibe/day, at least 4 months
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Richardson Centre for Functional Foods and Nutraceuticals
Winnipeg, Manitoba, R3T 2N2, Canada
Othman RA, Myrie SB, Mymin D, Roullet JB, DeBarber AE, Steiner RD, Jones PJH. Thyroid Hormone Status in Sitosterolemia Is Modified by Ezetimibe. J Pediatr. 2017 Sep;188:198-204.e1. doi: 10.1016/j.jpeds.2017.05.049. Epub 2017 Jun 16.
Othman RA, Myrie SB, Mymin D, Merkens LS, Roullet JB, Steiner RD, Jones PJ. Ezetimibe reduces plant sterol accumulation and favorably increases platelet count in sitosterolemia. J Pediatr. 2015 Jan;166(1):125-31. doi: 10.1016/j.jpeds.2014.08.069. Epub 2014 Oct 16.
Semone B Myrie, PhD
University of Manitoba
Peter J Jones, PhD
University of Manitoba
8 participants (actual enrollment reported by the registry).
First Submitted
April 16, 2012
First Posted
April 24, 2012
Study Start
April 2012
Date type not reportedThis date has not been verified as actual or estimated.
Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected Adults
Contact the study team to confirm eligibility.
Primary Completion
August 2013
Actual (reported)Study Completion
December 2016
Actual (reported)Last Updated
January 30, 2020
Record last verified: 2015-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: